thalidomide has been researched along with Breast Cancer in 32 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We examined the toxicity/efficacy of capecitabine with thalidomide, administered over 21-day cycles, in 24 previously treated metastatic breast cancer (MBC) patients." | 9.14 | Phase II study of capecitabine in combination with thalidomide in patients with metastatic breast cancer. ( Barton, JH; Burris, HA; Greco, FA; Hainsworth, JD; Jones, SF; Meluch, AA; Shipley, D; Yardley, DA, 2010) |
| "We previously demonstrated efficacy and impact on serum vascular endothelial growth factor (VEGF) for metronomic cyclophosphamide (C) and methotrexate (M) in patients with breast cancer." | 9.12 | Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. ( Colleoni, M; Ghisini, R; Goldhirsch, A; Maisonneuve, P; Nolè, F; Orlando, L; Peruzzotti, G; Rocca, A; Sandri, MT; Sanna, G; Viale, G; Zorzino, L, 2006) |
| "To determine the efficacy, safety, pharmacokinetics, and effect on serum angiogenic growth factors of two dose levels of thalidomide in patients with metastatic breast cancer." | 9.09 | Phase II evaluation of thalidomide in patients with metastatic breast cancer. ( Baidas, SM; Crawford, JG; Fleming, GF; Flockhart, D; Hanfelt, J; Harris, L; Hawkins, MJ; Hayes, DF; Isaacs, C; Johnson, MD; Lippman, ME; Pluda, JM; Tefft, M; Winer, EP; Yamauchi, H, 2000) |
| "we aimed to explore the role of thalidomide in breast cancer by using a mouse 4T1 breast tumor model." | 7.96 | Thalidomide suppresses breast cancer tumor growth by inhibiting tumor-associated macrophage accumulation in breast tumor-bearing mice. ( MengLv, L; Shen, Y; Wang, F; Wang, X; Yang, J; Zhang, X, 2020) |
| "Thalidomide, which inhibits angiogenesis in certain tumor types, reduced extravasation of a macromolecular contrast medium (MMCM) in a human breast cancer model as assayed by MMCM-enhanced dynamic magnetic resonance imaging (MRI) and fluorescence microscopy in the same tumors." | 7.75 | Magnetic resonance imaging for monitoring the effects of thalidomide on experimental human breast cancers. ( Brasch, RC; Chaopathomkul, B; Cyran, CC; Fu, Y; McDonald, DM; Rogut, VS; Sennino, B; Shames, DM; Wendland, MF, 2009) |
| "Thalidomide was first used for relief of morning sickness in pregnant women and then withdrawn from the market because of its dramatic effects on normal fetal development." | 5.46 | Old Drug Scaffold, New Activity: Thalidomide-Correlated Compounds Exert Different Effects on Breast Cancer Cell Growth and Progression. ( Carocci, A; Caroleo, MC; Catalano, A; Ceramella, J; Curcio, R; Iacopetta, D; Lentini, G; Sinicropi, MS, 2017) |
| "We studied whether lenalidomide treated breast cancer cells would acquire sensitivity to 1,25-D3 with resulting growth inhibition." | 5.38 | The immunomodulatory drug lenalidomide restores a vitamin D sensitive phenotype to the vitamin D resistant breast cancer cell line MDA-MB-231 through inhibition of BCL-2: potential for breast cancer therapeutics. ( Brosseau, C; Colston, K; Dalgleish, AG; Galustian, C, 2012) |
| "We examined the toxicity/efficacy of capecitabine with thalidomide, administered over 21-day cycles, in 24 previously treated metastatic breast cancer (MBC) patients." | 5.14 | Phase II study of capecitabine in combination with thalidomide in patients with metastatic breast cancer. ( Barton, JH; Burris, HA; Greco, FA; Hainsworth, JD; Jones, SF; Meluch, AA; Shipley, D; Yardley, DA, 2010) |
| "We previously demonstrated efficacy and impact on serum vascular endothelial growth factor (VEGF) for metronomic cyclophosphamide (C) and methotrexate (M) in patients with breast cancer." | 5.12 | Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. ( Colleoni, M; Ghisini, R; Goldhirsch, A; Maisonneuve, P; Nolè, F; Orlando, L; Peruzzotti, G; Rocca, A; Sandri, MT; Sanna, G; Viale, G; Zorzino, L, 2006) |
| "To determine the efficacy, safety, pharmacokinetics, and effect on serum angiogenic growth factors of two dose levels of thalidomide in patients with metastatic breast cancer." | 5.09 | Phase II evaluation of thalidomide in patients with metastatic breast cancer. ( Baidas, SM; Crawford, JG; Fleming, GF; Flockhart, D; Hanfelt, J; Harris, L; Hawkins, MJ; Hayes, DF; Isaacs, C; Johnson, MD; Lippman, ME; Pluda, JM; Tefft, M; Winer, EP; Yamauchi, H, 2000) |
| "we aimed to explore the role of thalidomide in breast cancer by using a mouse 4T1 breast tumor model." | 3.96 | Thalidomide suppresses breast cancer tumor growth by inhibiting tumor-associated macrophage accumulation in breast tumor-bearing mice. ( MengLv, L; Shen, Y; Wang, F; Wang, X; Yang, J; Zhang, X, 2020) |
| "Thalidomide, which inhibits angiogenesis in certain tumor types, reduced extravasation of a macromolecular contrast medium (MMCM) in a human breast cancer model as assayed by MMCM-enhanced dynamic magnetic resonance imaging (MRI) and fluorescence microscopy in the same tumors." | 3.75 | Magnetic resonance imaging for monitoring the effects of thalidomide on experimental human breast cancers. ( Brasch, RC; Chaopathomkul, B; Cyran, CC; Fu, Y; McDonald, DM; Rogut, VS; Sennino, B; Shames, DM; Wendland, MF, 2009) |
| "Thalidomide was administered as a therapeutic agent for chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation in a patient with breast cancer." | 3.69 | Thalidomide-induced perioral neuropathy. ( Elad, S; Galili, D; Garfunkel, AA; Or, R, 1997) |
| "The incidence of brain metastases from breast cancer is increasing with diagnosis and therapeutics progress, especially with systemic therapies." | 2.50 | [Radiotherapy plus concomitant systemic therapies for patients with brain metastases from breast cancer]. ( Cao, KI; Kirova, YM, 2014) |
| "The growth of breast cancers, as is the case in other solid tumors, is dependent on the development of neo-vessels." | 2.44 | [Angiogenesis and breast cancer]. ( Bachelot, T; Blay, JY; Cassier, P; Ray-Coquard, I, 2007) |
| "It is now well established that cancer growth is increased by angiogenic factors and that inhibition of angiogenesis decreases growth and metastatic potential." | 2.42 | [Anti angiogenesis]. ( Akaza, H; Blackledge, G; Carmichael, J; Isonishi, S; Kakeji, Y; Kurebayashi, J; Nakagawa, M; Nakamura, S; Ohashi, Y; Saijo, N; Sone, S; Tsuruo, T; Yamamoto, N, 2004) |
| "A 69-year-old female patient with breast cancer experienced severe skin itching and rashes on the face, anterior chest wall, back, and trunk for two days before admission." | 1.72 | A case report of secondary synchronous diagnosis of multiple myeloma and systemic lupus erythematosus after breast cancer treatment: A CARE-compliant article. ( Chen, PH; Huang, KP; Lin, CH; Lin, CY; Ni, YL; Tung, HH, 2022) |
| "Thalidomide was first used for relief of morning sickness in pregnant women and then withdrawn from the market because of its dramatic effects on normal fetal development." | 1.46 | Old Drug Scaffold, New Activity: Thalidomide-Correlated Compounds Exert Different Effects on Breast Cancer Cell Growth and Progression. ( Carocci, A; Caroleo, MC; Catalano, A; Ceramella, J; Curcio, R; Iacopetta, D; Lentini, G; Sinicropi, MS, 2017) |
| " The effect of the drug alone and in combination with radiotherapy using Cobalt 60 (60Co) at 45 Gy on the enzymatic activity of substance‑P degrading A disintegrin and metalloproteinase (ADAM)10 and neprilysin (NEP) was investigated in the mouse breast cancer cell lines 4T1 and 4T1 heart metastases post‑capsaicin (4THMpc)." | 1.42 | Thalidomide combined with irradiation alters the activity of two proteases. ( Aydemir, E; Fişkın, K; Korcum, AF; Şimşek, E, 2015) |
| "We studied whether lenalidomide treated breast cancer cells would acquire sensitivity to 1,25-D3 with resulting growth inhibition." | 1.38 | The immunomodulatory drug lenalidomide restores a vitamin D sensitive phenotype to the vitamin D resistant breast cancer cell line MDA-MB-231 through inhibition of BCL-2: potential for breast cancer therapeutics. ( Brosseau, C; Colston, K; Dalgleish, AG; Galustian, C, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.13) | 18.7374 |
| 1990's | 1 (3.13) | 18.2507 |
| 2000's | 15 (46.88) | 29.6817 |
| 2010's | 13 (40.63) | 24.3611 |
| 2020's | 2 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, PH | 1 |
| Tung, HH | 1 |
| Lin, CH | 1 |
| Huang, KP | 1 |
| Ni, YL | 1 |
| Lin, CY | 1 |
| Wang, X | 1 |
| Shen, Y | 1 |
| MengLv, L | 1 |
| Zhang, X | 1 |
| Yang, J | 2 |
| Wang, F | 1 |
| Muchowicz, A | 1 |
| Wachowska, M | 1 |
| Stachura, J | 1 |
| Tonecka, K | 1 |
| Gabrysiak, M | 1 |
| Wołosz, D | 1 |
| Pilch, Z | 1 |
| Kilarski, WW | 1 |
| Boon, L | 1 |
| Klaus, TJ | 1 |
| Golab, J | 1 |
| Cao, KI | 1 |
| Kirova, YM | 1 |
| El-Aarag, BY | 1 |
| Kasai, T | 1 |
| Zahran, MA | 1 |
| Zakhary, NI | 1 |
| Shigehiro, T | 1 |
| Sekhar, SC | 1 |
| Agwa, HS | 1 |
| Mizutani, A | 1 |
| Murakami, H | 1 |
| Kakuta, H | 1 |
| Seno, M | 1 |
| Şimşek, E | 1 |
| Aydemir, E | 1 |
| Korcum, AF | 1 |
| Fişkın, K | 1 |
| Martínez-Aranda, A | 1 |
| Hernández, V | 1 |
| Guney, E | 1 |
| Muixí, L | 1 |
| Foj, R | 1 |
| Baixeras, N | 1 |
| Cuadras, D | 1 |
| Moreno, V | 1 |
| Urruticoechea, A | 1 |
| Gil, M | 1 |
| Oliva, B | 1 |
| Moreno, F | 1 |
| González-Suarez, E | 1 |
| Vidal, N | 1 |
| Andreu, X | 1 |
| Seguí, MA | 1 |
| Ballester, R | 1 |
| Castella, E | 1 |
| Sierra, A | 1 |
| Aagre, S | 1 |
| Madabhavi, I | 1 |
| Patel, A | 1 |
| Anand, A | 1 |
| Panchal, H | 1 |
| Parikh, S | 1 |
| Iacopetta, D | 1 |
| Carocci, A | 1 |
| Sinicropi, MS | 1 |
| Catalano, A | 1 |
| Lentini, G | 1 |
| Ceramella, J | 1 |
| Curcio, R | 1 |
| Caroleo, MC | 1 |
| Cyran, CC | 1 |
| Sennino, B | 1 |
| Chaopathomkul, B | 1 |
| Fu, Y | 1 |
| Rogut, VS | 1 |
| Shames, DM | 1 |
| Wendland, MF | 1 |
| McDonald, DM | 1 |
| Brasch, RC | 1 |
| Burris, HA | 1 |
| Jones, SF | 1 |
| Shipley, D | 1 |
| Meluch, AA | 1 |
| Greco, FA | 1 |
| Barton, JH | 1 |
| Yardley, DA | 1 |
| Hainsworth, JD | 1 |
| Liu, WM | 1 |
| Gravett, AM | 1 |
| Dalgleish, AG | 2 |
| Otto, S | 1 |
| Schreyer, C | 1 |
| Hafner, S | 1 |
| Mast, G | 1 |
| Ehrenfeld, M | 1 |
| Stürzenbaum, S | 1 |
| Pautke, C | 1 |
| Shenoy, SK | 1 |
| Han, S | 1 |
| Zhao, YL | 1 |
| Hara, MR | 1 |
| Oliver, T | 1 |
| Cao, Y | 1 |
| Dewhirst, MW | 1 |
| Bos, R | 1 |
| de Waal, EG | 1 |
| Kuiper, H | 1 |
| Hazenberg, BP | 1 |
| Vellenga, E | 1 |
| Brosseau, C | 1 |
| Colston, K | 1 |
| Galustian, C | 1 |
| Raje, N | 1 |
| Anderson, KC | 1 |
| Mohla, S | 1 |
| Weilbacher, KN | 1 |
| Cher, ML | 1 |
| Oyajobi, BO | 1 |
| Poznak, CV | 1 |
| Clohisy, DR | 1 |
| Chaudhry, V | 1 |
| Chaudhry, M | 1 |
| Crawford, TO | 1 |
| Simmons-O'Brien, E | 1 |
| Griffin, JW | 1 |
| Burgermeister, J | 1 |
| Goldman, B | 1 |
| Lang, NP | 1 |
| Akaza, H | 1 |
| Nakagawa, M | 1 |
| Tsuruo, T | 1 |
| Saijo, N | 1 |
| Sone, S | 1 |
| Yamamoto, N | 1 |
| Kakeji, Y | 1 |
| Nakamura, S | 1 |
| Kurebayashi, J | 1 |
| Isonishi, S | 1 |
| Ohashi, Y | 1 |
| Blackledge, G | 1 |
| Carmichael, J | 1 |
| Colleoni, M | 3 |
| Orlando, L | 2 |
| Sanna, G | 1 |
| Rocca, A | 2 |
| Maisonneuve, P | 3 |
| Peruzzotti, G | 2 |
| Ghisini, R | 1 |
| Sandri, MT | 2 |
| Zorzino, L | 2 |
| Nolè, F | 1 |
| Viale, G | 1 |
| Goldhirsch, A | 2 |
| Mancuso, P | 1 |
| Calleri, A | 1 |
| Pruneri, G | 1 |
| Agliano, A | 1 |
| Shaked, Y | 1 |
| Kerbel, RS | 1 |
| Bertolini, F | 1 |
| Raina, V | 1 |
| Sengar, M | 1 |
| Shukla, NK | 1 |
| Deo, SS | 1 |
| Mohanty, BK | 1 |
| Sharma, D | 1 |
| Ray, R | 1 |
| Das, P | 1 |
| Rath, GK | 1 |
| Johansson, HA | 1 |
| Salvatici, M | 1 |
| Passerini, R | 1 |
| Bachelot, T | 1 |
| Ray-Coquard, I | 1 |
| Cassier, P | 1 |
| Blay, JY | 1 |
| Elad, S | 1 |
| Galili, D | 1 |
| Garfunkel, AA | 1 |
| Or, R | 1 |
| Baidas, SM | 1 |
| Winer, EP | 1 |
| Fleming, GF | 1 |
| Harris, L | 1 |
| Pluda, JM | 1 |
| Crawford, JG | 1 |
| Yamauchi, H | 1 |
| Isaacs, C | 1 |
| Hanfelt, J | 1 |
| Tefft, M | 1 |
| Flockhart, D | 1 |
| Johnson, MD | 1 |
| Hawkins, MJ | 1 |
| Lippman, ME | 1 |
| Hayes, DF | 1 |
| Eisen, TG | 1 |
| Worden, AN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Study of Thalidomide in Combination With Capecitabine in Patients With Metastatic Breast Cancer[NCT00193102] | Phase 2 | 40 participants (Anticipated) | Interventional | 2001-04-30 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for thalidomide and Breast Cancer
| Article | Year |
|---|---|
[Radiotherapy plus concomitant systemic therapies for patients with brain metastases from breast cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blood-Brain Barri | 2014 |
Thalidomide and immunomodulatory drugs as cancer therapy.
Topics: Adjuvants, Immunologic; Breast Neoplasms; Clinical Trials as Topic; Colonic Neoplasms; Humans; Immun | 2002 |
[Anti angiogenesis].
Topics: Angiogenesis Inhibitors; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Cyclooxyg | 2004 |
[Angiogenesis and breast cancer].
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineo | 2007 |
Thalidomide in solid tumors: the London experience.
Topics: Adult; Angiogenesis Inhibitors; Breast Neoplasms; Carcinoma, Renal Cell; Clinical Trials, Phase II a | 2000 |
Toxicology and the environment.
Topics: Abnormalities, Drug-Induced; Animals; Breast Neoplasms; Carcinogens; Contraceptives, Oral; Culture T | 1973 |
5 trials available for thalidomide and Breast Cancer
| Article | Year |
|---|---|
Phase II study of capecitabine in combination with thalidomide in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycy | 2010 |
Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineo | 2006 |
Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas | 2006 |
Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cy | 2007 |
Phase II evaluation of thalidomide in patients with metastatic breast cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Breast Neoplasms; Drug Administration Schedule; Endothelial Gr | 2000 |
21 other studies available for thalidomide and Breast Cancer
| Article | Year |
|---|---|
A case report of secondary synchronous diagnosis of multiple myeloma and systemic lupus erythematosus after breast cancer treatment: A CARE-compliant article.
Topics: Aged; Antibodies, Monoclonal; Breast Neoplasms; Female; Glycoproteins; Humans; Hydrocortisone; Hydro | 2022 |
Thalidomide suppresses breast cancer tumor growth by inhibiting tumor-associated macrophage accumulation in breast tumor-bearing mice.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Macrophages; Mice; Mice, Inbred BALB C; | 2020 |
Inhibition of lymphangiogenesis impairs antitumour effects of photodynamic therapy and checkpoint inhibitors in mice.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Cycle Checkpoints; D | 2017 |
In vitro anti-proliferative and anti-angiogenic activities of thalidomide dithiocarbamate analogs.
Topics: Angiogenesis Inhibitors; Breast Neoplasms; Cell Line; Cell Line, Tumor; Cell Proliferation; Female; | 2014 |
Thalidomide combined with irradiation alters the activity of two proteases.
Topics: ADAM Proteins; ADAM10 Protein; Amyloid Precursor Protein Secretases; Animals; Apoptosis; Breast Neop | 2015 |
FN14 and GRP94 expression are prognostic/predictive biomarkers of brain metastasis outcome that open up new therapeutic strategies.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Animals; Area Under Curve; Astrocytes; Biom | 2015 |
Primary Plurifocal Extramedullary Plasmacytoma of Breast.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Breast Neoplasms; Dexamethasone; | 2016 |
Old Drug Scaffold, New Activity: Thalidomide-Correlated Compounds Exert Different Effects on Breast Cancer Cell Growth and Progression.
Topics: Apoptosis; Breast Neoplasms; Cadherins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Epithel | 2017 |
Magnetic resonance imaging for monitoring the effects of thalidomide on experimental human breast cancers.
Topics: Angiogenesis Inhibitors; Animals; Breast Neoplasms; Disease Models, Animal; Magnetic Resonance Imagi | 2009 |
The antimalarial agent artesunate possesses anticancer properties that can be enhanced by combination strategies.
Topics: Antimalarials; Antineoplastic Combined Chemotherapy Protocols; Artemisinins; Artesunate; Blotting, W | 2011 |
Bisphosphonate-related osteonecrosis of the jaws - characteristics, risk factors, clinical features, localization and impact on oncological treatment.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2012 |
β-arrestin1 mediates metastatic growth of breast cancer cells by facilitating HIF-1-dependent VEGF expression.
Topics: Active Transport, Cell Nucleus; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; | 2012 |
Thalidomide and dexamethasone followed by autologous stem cell transplantation for scleromyxoedema.
Topics: Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Combined Modality Therapy; Dexamethasone; | 2011 |
The immunomodulatory drug lenalidomide restores a vitamin D sensitive phenotype to the vitamin D resistant breast cancer cell line MDA-MB-231 through inhibition of BCL-2: potential for breast cancer therapeutics.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Calcitriol; Cell Line, | 2012 |
Third North American Symposium on Skeletal Complications of Malignancy: summary of the scientific sessions.
Topics: Animals; Bone Marrow; Bone Neoplasms; Breast Neoplasms; Cell Transformation, Neoplastic; Clinical Tr | 2003 |
Toxic neuropathy in patients with pre-existing neuropathy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Dose-Respo | 2003 |
Head of German medicines body likens HRT to thalidomide.
Topics: Aged; Breast Neoplasms; Female; Germany; Hormone Replacement Therapy; Humans; Middle Aged; Risk Fact | 2003 |
For investigational targeted drugs, combination trials pose challenges.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; A | 2003 |
Molecular epidemiology: new insights into diagnosis and prognosis.
Topics: Alleles; Angiogenesis Inhibitors; Breast Neoplasms; Colonic Neoplasms; Female; Gene Expression; Glut | 2004 |
Complete response from thalidomide in angiosarcoma after treatment of breast cancer.
Topics: Aged; Breast Neoplasms; Female; Hemangiosarcoma; Humans; Thalidomide | 2007 |
Thalidomide-induced perioral neuropathy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adju | 1997 |